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Prevalence of hyposalivation and 
associated factors in survivors of 
head and neck cancer treated with 
radiotherapy
Hyposalivation and sensation of dry mouth (xerostomia) are one of the 
most common adverse effects in the treatment of patients with head and neck 
cancer. Objective: This study evaluates the prevalence of late hyposalivation 
and associated factors in survivors of squamous cell carcinoma of the oral 
cavity, oropharynx, hypopharynx, or larynx treated with radiotherapy with 
or without concomitant chemotherapy. Methodology: A cross-sectional 
study was conducted with 88 patients who had concluded radiotherapy at 
least three months before the study, at a referral center for the treatment 
of head and neck cancer in the Southern region of Brazil. Hyposalivation 
was evaluated based on the stimulated salivary flow rate using the spitting 
method. Multivariate analysis using binary logistic regression was performed 
to determine the associations between hyposalivation and clinical and 
demographic variables. Results: Hyposalivation was found in 78.41% of the 
sample and the mean radiation dose was 63.01 Gy (±9.58). In the crude 
model of the multivariate analysis, hyposalivation was associated with higher 
doses of radiation (p=0.038), treatment with concomitant radiotherapy and 
chemotherapy (p=0.005), and time elapsed since the end of radiotherapy 
(p=0.025). In the adjusted model of the multivariate analysis, hyposalivation 
was only associated with dose and time elapsed. Patient who received higher 
doses of radiation had a 4.25-fold greater chance of presenting hyposalivation, 
whereas a longer time elapsed since the end of radiotherapy exerted a 
75% protective effect against the occurrence of hyposalivation. Conclusion: 
Hyposalivation is a highly prevalence late-onset side effect of radiotherapy in 
patients treated for head and neck cancer, with a greater chance of occurrence 
among those who received higher doses of radiation and those who ended 
therapy less than 22 months before our study. Concomitant chemotherapy 
and radiotherapy does not seem to increase the chances of hyposalivation 
compared to radiotherapy alone. 
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Introduction
Cancer of the oral cavity, pharynx, and larynx 
corresponds to approximately 4.6% of all cases of 
cancer worldwide.1 In 2018, 834,860 new cases of 
cancer in these anatomic sites were diagnosed.1 When 
anatomic sub-sites are analyzed, the incidence of 
cancer of the mouth and oropharnyx is higher, followed 
by cancer of the larynx and hypopharynx.2 Due to 
demographic changes, the number of cases of lip, 
mouth, and pharyngeal cancer is expected to increase 
by 62%, reaching 856,000 cases annually by 2035.
Radiotherapy (RT) is widely employed in the 
treatment of head and neck cancer used as primary 
therapy, adjunct therapy to surgery, with concomitant 
chemotherapy (CT) or as palliative treatment. High 
doses of RT can negatively affect the soft and hard 
tissues of the oral cavity.3 Patients with head and neck 
cancer are generally irradiated with high doses (50 
to 70 Gy),4 which side-effects include hyposalivation, 
trismus, and dysphagia; in hard tissues, the effects 
may be osteoradionecrosis and radiation caries – all 
of which have a late-onset.3
One of the main problems resulting from 
radiotherapy in the head and neck region is the 
damage to glandular tissues, reducing the salivary 
flow.5 Hyposalivation occurs due to cell death and 
fibrosis of the glandular tissue caused by radiotherapy, 
leading to a sensation of dry mouth (xerostomia).6 
Some studies suggest a significant increase in late-
onset xerostomia in patients treated with concomitant 
chemotherapy and radiotherapy,7 whereas other 
authors state that there is no strong evidence of 
the additive effect of chemotherapy concomitant to 
radiotherapy on hypofunction of the salivary glands.8 
In a systematic review, Jensen, et al.8 (2010) found 
divergences in the literature regarding hyposalivation 
and xerostomia. According to some authors, the 
term xerostomia is often used as a synonym of 
hyposalivation, when it should only be used to indicate 
the perception of dry mouth reported by the patient.
Due to this common late effect in patients irradiated 
in head and neck and the influence on their quality 
of life, studies bringing new information to the 
field are necessary. Therefore, this study evaluates 
the prevalence and factors associated with late 
hyposalivation based on the stimulated salivary flow 
rate in patients treated with 3D conformal radiotherapy 
with or without concomitant chemotherapy for the 
treatment of cancer of the oral cavity, oropharynx, 
hypopharynx, or larynx. We hypothesize that a high 
prevalence would be found caused by high doses of 
radiation in the salivary glands and also influenced by 
the type of therapy used in this region in Southern 
Brazil.
Methodology
Study design, sample and eligibility criteria
An observational, quantitative, analytical, cross-
sectional study was conducted. Data were collected 
from April 2016 to May 2017 at the Head and Neck 
Surgery outpatient clinic of the Federal University 
of Santa Maria hospital, which is the largest public 
hospital in the central region of the state of Rio Grande 
do Sul, Brazil, and a reference for the treatment of 
head and neck cancer. Survivors of cancer of the 
oral cavity, oropharynx, hypopharynx, or larynx who 
had undergone 3D conformal radiotherapy and had 
completed treatment at least three months prior to the 
process of data collection were screened for eligibility. 
The inclusion criteria were men or women aged 18 
years or older, presumably disease free who agreed 
to undergo the proposed examinations. 
The sample size was calculated based on the 
difference in mean non-stimulated salivary flow 
between individuals exposed to a radiation dose of 50 
Gy and non-exposed individuals in a previous study: 
0.47 (SD: 0.31) and 0.28 (SD: 0.32), respectively.9 
Considering a 5% significance level and 80% power, 
a minimum of 59 participants was needed. Due 
to the multivariate analysis and the possibility of 
dropouts, considering the participants’ vulnerability, 
the sample size was increased by 30% (minimum of 
85 participants).
This study was approved by the Human Research 
Ethics Committee of the Federal University of Santa 
Maria (certificate number: 1.387.994/2016). All 
participants signed an informed consent form. 
Data collection
Demographic characteristics (age, sex, and 
ethnicity), lifestyle habits (smoking and alcohol use), 
comorbidities (defined as any condition able to modify 
salivary flow, as diabetes mellitus, Sjogren syndrome, 
or hypothyroidism, and/or use of drugs that can 
induce salivary gland hypofunction and/or xerostomia, 
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as antihypertensive agents, antidepressant and 
others)10,11 as well as data regarding the disease 
(tumor type and stage) and treatment (type and 
dose of radiation) were collected from the patient 
medical charts. Xerostomia (subjective assessment) 
was recorded based on the answer to the following 
question: “Does your mouth generally feel dry?”12,13
   
  Saliva collection and sialometry - stimulated 
salivary flow
The participants were instructed not to eat, drink 
(except water) or smoke at least one hour prior to 
the saliva collection. Stimulated salivary flow rate was 
determined using the spitting collection method.14 The 
mechanical stimulation of salivation was performed 
with a sterile rubber strip with a standardized size 
(2x2 cm). The collection lasted five minutes. All saliva 
collection procedures were held between 13:30 and 
3:30 pm. The participant was seated comfortably 
on a chair and were instructed neither to speak nor 
interrupt the data collection process; otherwise, a new 
collection would be initiated. The saliva from the first 
minute was discarded to eliminate possible food scraps 
that could influence the weight of the saliva. Then, the 
participant expelled saliva into a previously sterilized 
and weighed universal collector at 60-second intervals. 
The collection time was controlled with a chronometer. 
The total quantity of stimulated saliva was determined 
based on weight measured using a precision scale 
(Balança Eletrônica Gehaka BG 200) expressed in 
grams. The total weight was divided by four (because 
the first minute was discarded) to obtain the salivary 
flow rate in grams per minute, which is similar to mL/
min. Hyposalivation was recorded if the stimulated 
salivary flow rate was less than 0.5 mL/min.15 
Radiation caries
Ring-shaped caries on the cervical third of the 
vestibular, incisal, occlusal, and lingual faces of the 
teeth were considered radiation caries,4 which were 
detected through a visual clinical examination aided 
by a wooden tongue depressor with the patient lying 
on the dental chair. The clinical examinations were 
performed by two raters who had previously undergone 
training and calibration exercises. The calibration 
involved the examination of 20 images displayed on 
a computer screen one at a time, for which the raters 
marked “yes” or “no” on a chart. The procedure was 
repeated after 30 days. The Kappa coefficient was 
estimated for the determination of intra-rater and 
inter-rater agreement (K=0.79 to 1.00). 
Statistical analysis
The data were analyzed descriptively, with the 
calculation of mean, standard deviation, and median 
values. The Kolmogorov-Smirnov and Shapiro-Wilk 
tests were used to determine the normality of the 
variables distribution. For the purposes of statistical 
analysis, age (62 years), time elapsed since the end 
of RT (22 months), and total radiation dose (66 Gy) 
were dichotomized by the median. Other variables 
were also dichotomized for statistical purposes. Tumor 
location was dichotomized as mouth/oropharynx 
or hypopharync/larynx. Tumor stage was classified 
as AJCC staging system 7th edition16 and it was 
dichotomized as initial (stages I and II) or advanced 
(stages III and IV). Type of treatment was dichotomized 
as RT without CT or RT with CT. Stimulated salivary 
flow and xerostomia were compared between patients 
with and without hyposalivation using Fischer’s exact 
test and the Mann-Whitney test, with 5% significance 
level.
Binary logistic regression models were run to 
evaluate associations between hyposalivation and 
covariables. The following categorical variables were 
evaluated in the crude model: age, tumor location, 
stage, type of treatment, time elapsed since the end 
of treatment, radiation doses and comorbidities/
medications that cause xerostomia. Variables with 
high p-value were removed from the model and only 
those with a p-value <0.20 were incorporated into 
the adjusted model. Data were analyzed using the 
Statistical Package for the Social Sciences (SPSS, 
version 21.0, PASW, Chicago, IL, USA).
Results
The response rate was 89.79% (88/98). Ten cases 
were excluded because participants were unable to 
remain until the completion of all examinations due 
to public transportation schedule. Thus, the sample 
was composed of 73 men and 15 women (mean age: 
62.74±9.70 years) with malignant tumors of the 
mouth/oropharynx (59.51%), larynx (35.2%), and 
hypopharynx (5.7%). Most cases were in the advanced 
stage (68.2%). Table 1 shows the complete description 
of the sample.
Hyposalivation was found in 69 individuals 
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(78.41%), among whom mean stimulated salivary flow 
was 0.21 mL/min (±0.16). Mean stimulated salivary 
flow among the patients without hyposalivation was 
1.25 mL/min (p<0.001). Xerostomia was reported 
by 82 participants (93.2%). An association was 
found between the perception of xerostomia and 
the objective assessment of salivary flow (p=0.018) 
(Table 2).
The patients received different cancer treatment 
modalities: RT alone (6.8%), surgery + RT (19.3%), 
surgery + RT + CT (37.5%) and RT + CT (36.4%). In 
the crude analysis, an association was found between 
Without Hyposalivation With Hyposalivation
n (%) n (%)
With Hyposalivation
≤ 62 (median) 10 (52.6) 39 (56.5)
> 62 9 (47.4) 30 (43.5)
Sex
Female 2 (10.5) 13 (18.8)
Male 17 (89.5) 56 (81.2)
Skin color
White 15 (78.9) 62 (89.9)
Non-white 4 (21.1) 7 (10.1)
Location*
Mouth/oropharynx 8 (42.1) 44 (63.8)
Hypopharynx 1 (5.3) 4 (5.8)
Larynx 10 (52.6) 21 (30.4)
Stage*
I 4 (21.1) 11 (15.9)
II 1 (5.3) 12 (17.4)
III 10 (52.6) 15 (21.7)
IV 4 (21.1) 31 (44.9)
Type of treatment*
Radiotherapy 2 (10.5) 4 (5.8)
Surgery + Radiotherapy 8 (42.1) 9 (13.0)
Surgery + Radiotherapy + Chemotherapy 7 (36.8) 26 (37.7)
Radiotherapy + Chemotherapy 2 (10.5) 30 (43.5)
Time elapsed since radiotherapy*
≤ 22 months (median) 5 (26.3) 39 (56.5)
> 22 months 14 (73.7) 30 (43.5)
Dose (Gy*)
≤ 66 Gy (median) 14 (77.8) 33 (49.3)
> 66 Gy 4 (22.2) 34 (50.7)
Dentition
Normal 1 (5.3) 6 (8.7)
Partially edentulous 13 (68.4) 47 (68.1)
Edentulous 5 (26.3) 16 (23.2)
Radiation caries
No 9 (64.3) 36 (67.9)
Yes 5 (35.7) 17 (32.1)
Comorbidities/xerostomic drugs
No 12 (63.2) 30 (43.5)
Yes 7 (36.8) 39 (56.5)
* dichotomized for statistical analysis; a chi-squared test; b Fisher’s exact test
Table 1- Distribution of demographic and clinical variables in groups with and without hyposalivation
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type of treatment and hyposalivation. Patients who 
had been treated with RT + CT had a 4.79-fold greater 
chance of presenting hyposalivation than those who 
had not been treated with concomitant chemotherapy 
(p=0.005). Radiation dose and time elapsed since 
the end of radiotherapy were also associated with 
hyposalivation in the crude analysis. Mean radiation 
dose was 63.01 Gy (±9.58) and higher doses were 
associated with a greater chance of exhibiting 
hyposalivation (p=0.038). Time elapsed since the 
end of the radiotherapy ranged from three to 192 
months. A shorter time since the end of treatment 
was associated with a greater chance of hyposalivation 
(p=0.025). After the adjustment for possible 
confounding variables, time since the end of treatment 
(p=0.022), and radiation dose (p=0.024) remained 
significantly associated with the outcome. Patients who 
had received higher doses of radiation had a 4.25-fold 
greater chance of having hyposalivation. A longer time 
elapsed since the end of treatment exerted a protective 
effect, denoting a 75% lower chance of hyposalivation 
(Table 3). Hyposalivation was not associated with age, 
sex, location of primary tumor, or radiation caries.
Figures 1, 2, and 3 show the mean rate of 
stimulated salivary flow as a function of the time 
elapsed since radiotherapy in total sample, in patients 
treated with radiotherapy and in patients treated with 
radiotherapy plus chemotherapy, respectively.
Total Without hyposalivation With hyposalivation p
(n = 19) (n = 69)
SSF* (mL/min)
Mean ± standard deviation 0.43 (±0.62) 1.25 (± 0.94) 0.21 (± 0.16) <0.001a
Median (P25-P75) 0.88 (0.64 – 1.39) 0.22 (0.03 – 0.36)
Xerostomia
No 6 (6.8%) 4 (21.1%) 2 (2.9%) 0.018b
Yes 82 (93.2%) 15 (78.9%) 67 (97.1%)
*SSF: stimulated salivary flow; a Mann-Whitney test; b Fisher’s exact test
Table 2- Stimulated salivary flow rate (mL/min) and perception of xerostomia in patients with and without hyposalivation
Hyposalivation OR (95% CI) p* OR (95% CI) p**
N (%) Crude Adjusted
Location - -
Mouth/oropharynx 44 (63.8) 1 0,094
Hypopharynx and larynx 25 (36.2) 0.41 (0.15 – 1.16)
Chemotherapy
No 13 (18.8) 1 0,005 - -
Yes 56 (81.2) 4.79 (1.62 – 14.15)
Dose (Gy)
≤ 66 33 (47.8) 1 0,038 1 0,024
> 66 34 (49.3) 3.61 (1.08 – 12.09) 4.25 (1.21 – 14.94)
Time since radiotherapy
≤ 22 months 39 (56.5) 1 0,025 1 0,022
> 22 months 30 (43.5) 0.28 (0.09 – 0.85) 0.25 (0.08 – 0.82)
Comorbidities/ drugs that cause xerostomia
No 30 (43.5) 1 0,133 - -
Yes 39 (56.5) 2.23 (0.78 – 6.35)
Crude* and adjusted** binary logistic regression; OR: odds ratio
(-): variables not retained in final model
Variables analyzed: age, tumor location, stage, time elapsed since the end of treatment, radiation dose, type of treatment and comorbidities/
xerostomic drugs; Only variables with p-value < 0.20 in the crude model were incorporated into the adjusted model.
Table 3- Associations between hyposalivation and demographic, behavioral and clinical variables
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Discussion
In this study, hyposalivation and associated 
factors were evaluated in patients who underwent 
radiotherapy of the head and neck. The prevalence 
of hyposalivation was high and it was associated with 
both higher doses of radiation and shorter time since 
the end of radiotherapy treatment. Previous studies 
have demonstrated that the adverse effects on the 
soft tissues (particularly the salivary glands) and hard 
tissues of the oral cavity are directly proportional to 
the radiation dose and the type of radiotherapy.17,18
Some studies offer information on threshold doses 
of radiation to avoid harm to the salivary glands and 
consequent occurrence of hyposalivation. Marks, et 
al.19 (1981) found that a dose from 30 to 40 Gy was 
able to cause an accentuated reduction in salivary flow. 
Moretto, Rampino, and Munoz20 (2014) demonstrated 
that 32 Gy is the average dose to spare the parotid 
gland from harm. Blanco, et al.18 (2005) estimated that 
Figure 1- Mean stimulated salivary flow as function of time elapsed since radiotherapy, in the total sample
Figure 2- Mean stimulated salivary flow according to time in patients treated with radiotherapy
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a mean dose of 25.8 Gy reduced the flow from a single 
parotid gland to 25% of its pre-treatment amount, 
regardless of the radiotherapy method. Therefore, 
the fact that the patients in this study received a 
mean radiation dose of 63.01 Gy explains the high 
prevalence of hyposalivation in the sample.
Another significant finding of this investigation was 
the protective effect of the time elapsed since the end 
of radiotherapy on salivary flow. A longer time since 
the end of the therapy was associated with a lower 
chance of presenting hyposalivation. Despite the 
cross-sectional design of this study, simulated salivary 
flow was greater in those who had finished treatment 
a longer period of time before the evaluation, 
especially 36 months earlier. Previous studies have 
also demonstrated salivary flow recovery over time. 
Eisbruch, et al.21 (1999) found a 78.4% reduction in 
stimulated salivary flow one month after irradiation 
compared to the pre-radiation period; one year 
after radiotherapy, median stimulated salivary flow 
was 114% of pre-radiation amount, suggesting the 
complete recovery of saliva production. The authors 
also found that the salivary flow recovery from the 
parotid gland occurred with doses up to 25 to 30 Gy, 
suggesting that the recovery of glandular tissues and 
the consequent improvement in salivary flow depends 
on the radiation dose. 
Jensen, et al.8 (2010) found that non-stimulated 
and stimulated salivary flow rates were lower during 
radiotherapy and diminished further from one to three 
months after the treatment. The authors also found a 
slight increase in stimulated salivary flow six months 
after treatment and in non-stimulated salivary flow one 
year after treatment. Other authors state that salivary 
gland recovery occurs, on average, within two years 
after the completion of radiotherapy.22,23
Radiotherapy with concomitant chemotherapy is 
the protocol of treatment for patients with epidermoid 
carcinoma of the head and neck in advanced stages 
whether as definitive treatment for the preservation 
of the organ or indicated for patients at high-risk in 
the postoperative period.24 In our study, a strong 
association was found between RT + CT and the 
reduction in stimulated salivary flow in the crude 
analysis, but this association was lost after controlling 
for confounding variables in the adjusted multivariate 
analysis.
Some studies have found a statistically significant 
association between RT + CT and the subjective 
symptom of xerostomia,7,25 but the authors did not 
assess salivary flow. Hey, et al.26 (2009) reported 
lower doses of tolerance for radiotherapy with 
concomitant chemotherapy in patients who received 
cisplatin as the chemotherapeutic drug. The dose 
tolerated by patients who received RT + CT was at 
least 7 to 8 Gy lower that that tolerated by patients 
who received radiotherapy alone. These findings 
demonstrate a greater tendency toward damage to 
the tissue of the parotid gland caused by radiotherapy 
with concomitant chemotherapy. However, other 
authors state that no concrete conclusion can be 
drawn regarding the additive effect of chemotherapy 
Figure 3- Mean stimulated salivary flow according to time in patients treated with radiotherapy plus chemotherapy
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associated with radiotherapy on harm to the salivary 
glands leading to hyposalivation.8 According to Chao, 
et al.27 (2001), neither the treatment modality (with 
or without chemotherapy) nor the radiation technique 
(intensity-modulated radiation therapy [IMRT] or non-
IMRT) exert an independent influence on the functional 
outcome for the salivary glands; only the dose exerts 
such an influence. Few studies have examined the 
long-term effect of chemotherapy. Meurman, et al.28 
(1997) followed up patients with lymphoma for up to 
five years after chemotherapy and found no changes 
in stimulated or non-stimulated salivary flow. 
The divergences in the findings reported in the 
literature may be due to the fact that some studies 
only compared xerostomia with the type of treatment 
(without measuring salivary flow) or due to the type 
of analysis performed. Some studies report that 
the evaluation of xerostomia alone is not a secure 
indicator of a reduction in saliva production.13 This 
may be explained by the change in the composition 
of saliva caused by chemotherapy.29 In this study, 
an association was found between xerostomia and 
hyposalivation, as patients who reported a sensation 
of dry mouth had a low stimulated salivary flow rate. 
Nonetheless, no association was found between RT 
+ CT and hyposalivation in the adjusted multivariate 
analysis, despite the fact that the crude analysis 
suggested such association.
In the literature, the minimum cutoff point for 
total stimulated salivary flow ranges from 0.5 to 0.7 
mL/min. In our study, hyposalivation was defined as 
a stimulated salivary flow rate of less than 0.5 mL/
min, as suggested by Sreebny15 (2000). Considering 
the participants’ mean age and the fact that more 
than half of the sample had comorbidities and/or 
used medications that could reduce salivary flow 
and, mainly, it is a sample composed of patients who 
had their head and neck irradiated, we found it more 
prudent to use the criterion that represented a more 
significant reduction in the total volume of stimulated 
salivary flow. Regarding xerostomia, different from 
other authors,30 we used a tool easier to apply in 
order to assess this variable,12,13 once the main 
purpose of the study was the objective assessment 
of hyposalivation.
This investigation has limitations that should 
be addressed. It was a cross-sectional study and 
no evaluations of salivary flow or xerostomia were 
performed in the pre-radiotherapy period. It was also 
not possible to measure the average radiation dose 
received in isolation by the parotid gland. Moreover, 
we did not exclude individuals who took medications 
that cause xerostomia, such as anti-hypertensive 
agents or antidepressants, or those participants who 
had some comorbidity that could cause xerostomia, 
such as diabetes. However, this possible bias was 
minimized by the inclusion of these independent 
variables in the statistical analysis. Comorbidities 
and xerostomic drugs that could reduce salivary 
flow had no statistically significant association with 
hyposalivation in both crude analysis or multivariate 
analysis adjusted for confounding variables. 
Studies have demonstrated that IMRT produces 
less toxicity and fewer adverse effects compared to 3D 
conformal radiotherapy.31,32 All individuals in the study 
had been submitted to the latter form of radiotherapy, 
which may explain the findings. Despite the known 
benefits of IMRT, 3D-conformal radiotherapy continues 
to be widely employed in Brazil – particularly at public 
health services –, similar to what occurs in other 
countries, where patients do not have the opportunity 
to benefit from newer techniques due to the financial 
restrictions of public hospitals. 
In brief, this study offers significant results that 
contribute to knowledge regarding hyposalivation 
and associated factors at a reference hospital in 
head and neck cancer treatment in Southern region 
of Brazil. This research will provide new information 
to the literature, drawing the attention of dentists 
and health professionals to this late adverse effect of 
radiotherapy, consequently leading to an improvement 
in prevention and treatment of these head and neck 
cancer patients. The results can be extrapolated to 
populations with similar conditions. 
Conclusion
Hyposalivation is a significant late-onset side 
effect of radiotherapy, with a high prevalence 
rate among patients submitted to irradiation of 
the head and neck region. This condition is also 
dose dependent. Chemotherapy concomitant to 
radiotherapy does not seem to increase the chances 
of hyposalivation compared to radiotherapy alone. 
A better understanding of the causes and factors 
that expose patients to a greater chance of having 
hyposalivation is essential to the development of 
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preventive strategies and support therapies that can 
minimize the harm caused to patients. 
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